2,208
Views
4
CrossRef citations to date
0
Altmetric
Myeloproliferative Disease

A review of therapy-related myelodysplastic syndromes and acute myeloid leukaemia (t-MDS/AML) in Irish patients: a single centre experience

ORCID Icon, , , , ORCID Icon, , & show all

References

  • Vardiman JW, Arber DA, Brunning RD, et al. Therapy-related myeloid neoplasms. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon, France: IARC Press; 2008, p. 127–129.
  • Larson RA. Cytogenetics, not just pervious therapy determines the course of therapy-related myeloid neoplasms. J Clin Oncol. 2012;30:2300–2302. doi: 10.1200/JCO.2011.41.1215
  • Larson RA. Therapy-related myeloid neoplasms. Haematologica. 2009;94:454–459. doi: 10.3324/haematol.2008.005157
  • Smith SM, Le Beau MM, Huo D, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood. 2003;102:43–52. doi: 10.1182/blood-2002-11-3343
  • Bhatia S. Therapy-related myelodysplasia and acute myeloid leukemia. Semin Oncol. 2013;40(6):666–675. doi: 10.1053/j.seminoncol.2013.09.013
  • Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419–425. doi: 10.1182/blood-2005-10-4149
  • Nomdedeu M, Calvo X, Pereira A, et al. Clinical features and prognostic assessment in 233 patients with therapy-related myelodysplastic syndromes: The IPSS-r is a powerful predictor of outcome. 2014. American Society of Haematology (ASH) Meeting. Abstract 4636.
  • Bally C, Fenaux P, Ades L. Azacitidine in the treatment of therapy-related MDS/AML: a report on 54 patients by GFM. Leukaemia Res. 2013;37(6):637–640. doi: 10.1016/j.leukres.2013.02.014
  • Fianchi L, Criscuolo M, Lunghi M, et al. Outcome of therapy related myeloid neoplasms treated with Azacitidine. J Haematol Oncol. 2012;5:44. doi: 10.1186/1756-8722-5-44

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.